Studienteam Lahn-Dill-Siegerland GbR
- Address
- Schanzenfeldstrasse 12, 35578 Wetzlar, Germany
Immune System Diseases
The Rheumatology department at Studienteam Lahn-Dill-Siegerland GbR focuses on conditions such as psoriasis, psoriatic arthritis and Rheumatoid Arthritis, aiming to improve patient outcomes by testing new therapeutic approaches and assessing safety.
- Safety evaluation of vaccines in patients with chronic inflammatory skin disease
- Comparative effectiveness of monotherapy versus combination therapy for rheumatoid arthritis
- Exploration of disease‑modifying agents targeting immune pathways
Researchers at the Wetzlar site collaborate to advance treatment options for immune‑mediated disorders while ensuring patient safety.
Immune System Processes
Studies investigate how the immune system reacts to emerging therapies, including the immunologic response to a vaccine and the distribution of bimekizumab across the body, with the goal of optimizing disease control.
- Monitoring immune activation markers during vaccination
- Pharmacokinetic profiling of biologic agents in adults
- Assessing the impact of targeted therapies on inflammatory pathways
The site’s work contributes to a deeper understanding of immune mechanisms underlying rheumatic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studienteam Lahn-Dill-Siegerland GbR
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic and Safety Study of Bimekizumab via Different Routes of Administration in Adults with Chronic Cutaneous Inflammation | UCB Biopharma | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lutikizumab | 1 | Unknown | 2025-10-20 | 2025-10-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.